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M I C R O B I O L O G Y
Microbiome-derived carnitine mimics as previously 
unknown mediators of gut-brain axis communication
Heather Hulme1, Lynsey M. Meikle1, Nicole Strittmatter2, Justin J. J. van der Hooft3, John Swales2, 
Ryan A. Bragg4, Victor H. Villar5, Michael J. Ormsby1, Stephanie Barnes6, Sheila L. Brown7, 
Alex Dexter8, Maya T. Kamat1, Jasper C. Komen9, Daniel Walker1, Simon Milling1,  
Emily K. Osterweil6, Andrew S. MacDonald7, Chris J. Schofield10, Saverio Tardito5,11, 
Josephine Bunch8,12, Gillian Douce1, Julia M. Edgar1,13, RuAngelie Edrada-Ebel14,  
Richard J. A. Goodwin2, Richard Burchmore1, Daniel M. Wall1*
Alterations to the gut microbiome are associated with various neurological diseases, yet evidence of causality 
and identity of microbiome-derived compounds that mediate gut-brain axis interaction remain elusive. Here, 
we identify two previously unknown bacterial metabolites 3-methyl-4-(trimethylammonio)butanoate and 
4-(trimethylammonio)pentanoate, structural analogs of carnitine that are present in both gut and brain of specific 
pathogen–free mice but absent in germ-free mice. We demonstrate that these compounds are produced by 
anaerobic commensal bacteria from the family Lachnospiraceae (Clostridiales) family, colocalize with carnitine in 
brain white matter, and inhibit carnitine-mediated fatty acid oxidation in a murine cell culture model of central 
nervous system white matter. This is the first description of direct molecular inter-kingdom exchange between 
gut prokaryotes and mammalian brain cells, leading to inhibition of brain cell function.
INTRODUCTION
While the microbiome can exert a degree of protection against 
invading pathogens, substantial and lasting changes in its composition 
are linked to many diseases that until recently were thought to be 
independent of microbial influence. Recent work has demonstrated that 
the microbiome is also fundamentally changed in many neurological 
conditions including multiple sclerosis, Parkinson’s disease, autism 
spectrum disorders (ASDs), Alzheimer’s disease, and chronic fatigue 
syndrome (1, 2). Although little conclusive evidence supports a caus-
ative role for the microbiome in neurological disease, bidirectional 
communication between the gut microbiome and the brain is now 
recognized as an important mediator of neurological health. Studies in 
animal models underscore the importance of a stable microbiome, 
as its disruption, particularly at key developmental stages, results in 
long-term effects on anxiety, development, and behavior (3). In ad-
dition, positive effects of gut bacterial supplementation on the brain 
are reported, while the positive outcomes of therapeutic interventions 
in some cases can be attributed to the gut microbiota (4).
Microbes stimulate host neurotransmitter production in the gut 
and synthesize their own host-recognized neurotransmitters (5, 6). 
They can also stimulate the host immune system, leading to inflam-
mation and notable shifts in composition of the gut microbiota with 
the potential to exert neurological effects (7). While microbial- 
derived molecules such as short-chain fatty acids can cross into the 
brain to exert their effects, most microbial molecules that influence 
the microbiome-gut-brain (MGB) axis mediate their effects indirectly 
through the highly enervated gut and the vagus nerve (8, 9).
RESULTS
To identify unknown microbial metabolites that mediate MGB axis 
communication, we used mass spectrometry imaging (MSI) to 
identify molecules that are present in both the gut and brain of 
specific pathogen–free (SPF) C57BL/6 mice but are absent from 
germ-free (GF) C57BL/6 mice. This approach enables the identifi-
cation of both known and novel molecules, with high spatial resolution. 
We detected a molecule at a mass-to-charge ratio (m/z) of 160.133 
by matrix- assisted laser desorption/ionization (MALDI)–MSI and 
desorption electrospray ionization (DESI)–MSI in the gut and brain 
of SPF mice at levels greater than 20 times higher than in corre-
sponding tissue sections from GF mice (Fig. 1 and fig. S1). MALDI- 
MSI was used to gain a high lateral resolution image for brain 
region analysis, and DESI-MSI was used for further high spectral 
resolution analysis. The detection of the molecule at m/z 160.133 in 
GF mice was comparable to a baseline off tissue negative control 
(fig. S1). This molecule, provisionally termed Met1, was particularly 
abundant in white matter areas of the brain (medulla, corpus callosum, 
and the arbor vitae) (Fig. 1B). Met1 was also detected systemically 
in wild-type C57BL/6 mice, in blood, liver, kidney, lung, spleen, 
intestine, testes, and heart (fig. S2).
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As detection of Met1 in GF mice was comparable to the negative 
control, this suggested a microbial origin for the compound in SPF mice. 
Therefore, we determined whether Met1 in the colon could be reduced 
by treatment for 7 days with a cocktail of nonabsorbable antibiotics. 
This treatment was seen to significantly reduce Met1 levels (P ≤ 0.05), 
underscoring the likely microbial origin of Met1 (fig. S3). We next 
screened intestinal bacterial strains from the gut microbiota of C57BL/6 
mice for the production of Met1. Bacterial strains isolated from mu-
rine feces were grown on fastidious anaerobe broth (FAB) agar plates 
before colonies were resuspended in phosphate- buffered saline 
(PBS) and spotted onto glass slides for screening for Met1 by MSI. 
A peak at m/z 160.133 was detected in two closely related bacterial 
strains from the Clostridium XIVa cluster of the Lachnospiraceae 
family, determined by 16S ribosomal DNA (rDNA) sequencing to 
be Clostridium clostridioforme and Clostridium symbiosum (Fig. 2). 
Both strains are enteric spore-forming human gut commensals that 
are obligately anaerobic, while C. clostridioforme is also an opportu-
nistic pathogen (10).
Other clostridial strains tested here did not produce this mole-
cule, and its production was not detected in all C. clostridioforme 
strains tested, including the C. clostridioforme type strain NCTC11224 
(Fig. 2). To ensure that the bacterial metabolite was Met1, rather 
than a structural isomer, we carried out tandem mass spectrometry 
(MS/MS) analysis of the bacterial metabolite at m/z 160.133 from 
C. clostridioforme and Met1 from the murine brain. The Met1 product 
ion spectra from the different sources matched, confirming that the 
molecules from the murine brain and C. clostridioforme were struc-
turally identical (fig. S4). On the basis of the acquired MS/MS spectra, 
we concluded that Met1 is similar in structure to carnitine, as two 
indicative mass fragments for a trimethylamine group were observed 
(m/z 58.066 and m/z 60.081) along with the mass difference of a 
carboxylic acid group (the difference between product ions at m/z 
101.060 and m/z 55.055). Furthermore, the MS/MS spectra generated 
appeared highly similar to that previously reported for 5-aminovaleric 
acid betaine (5-AVAB; also known as N-trimethyl-5-aminovalerate), 
which has an identical m/z 160.133 (11). However, during MS/MS 
fragmentation, we noted distinct differences in the intensity of 
the peaks at m/z 60.081 and m/z 55.055 at higher collision energies 
between Met1 and a synthesized 5-AVAB standard, leading us to 
doubt that Met1 was 5-AVAB (fig. S5). To definitively elucidate the 
structure, we subjected the bacterial fraction containing Met1 to nuclear 
magnetic resonance (NMR) correlation spectroscopy (1H-1H COSY). 
Fig. 1. MALDI-MSI on brain and gut sections from C57BL/6 GF and SPF mice. (A) Hematoxylin and eosin-stained sections (top) and MALDI-MSI images (bottom) of brain 
tissue. MALDI-MSI identified a peak at m/z 160.133 that was absent in GF mice but present in discrete locations in the brains of SPF mice. (B) Bar plot of relative abundance 
of m/z 160.1 in different regions of the SPF brain and the average across the whole brain. (C) This metabolite was also present in the SPF colon but absent in the GF colon. 
a.u., arbitrary units. Annotated brain regions: Cb, cerebellum; arb, arbor vitae; MO, medulla oblongata; P, pons; MB, midbrain; cc, corpus callosum; fr, fasciculus retroflexus. 
The heatmap intensity bar shows the color scale from low levels of the molecule (black/dark blue) to high levels of the molecule (pink/white). Scale bars, 1 mm.
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NMR determined that Met1 was a mixture of two structural isomers 
differing only in the location of a methyl side chain, located on either 
C3 [3-methyl-4-(trimethylammonio)butanoate (3M-4-TMAB)] or C4 
[4-(trimethylammonio)pentanoate (4-TMAP)] of the structure (Fig. 3). 
NMR analysis also showed that the metabolites were produced in 
an equimolar ratio by the bacteria alongside the congener molecule 
-butyrobetaine (GBB). Detection of GBB alongside 3M-4-TMAB 
and 4-TMAP in C. clostridioforme suggests that it may be the pre-
cursor of these molecules, as well as being the direct precursor of 
carnitine. However, unlike 3M-4-TMAB and 4-TMAP, GBB is syn-
thesized by a range of intestinal bacteria as well as mammalian cells, 
meaning that tracking GBB produced specifically by the bacterial 
producers of 3M-4-TMAB and 4-TMAP was not possible.
Because 3M-4-TMAB is highly similar in structure to carnitine 
and 4-TMAP is similar to GBB, the direct precursor of carnitine, we 
used MSI to examine colocalization of 3M-4-TMAB and 4-TMAP 
with carnitine in SPF mouse brain slices. Carnitine is a crucial me-
diator of fatty acid oxidation (FAO), shuttling long-chain fatty acids 
in the form of acylcarnitines across the membrane into mitochondria 
where they are broken down. Carnitine visualization was performed 
using MALDI-MSI, and DESI-MSI was used to gain an accurate m/z 
(162.112) for subsequent identification (Fig. 4). Mass spectra from 
MALDI-MSI and DESI-MSI of m/z 160.1 and m/z 162.1 are shown 
in fig. S6. Processing of MSI images of 3M-4-TMAB/4-TMAP and 
carnitine was performed using SpectralAnalysis (12). The overlap of 
high-intensity regions of m/z 160.1 (3M-4-TMAB and 4-TMAP) and 
m/z 162.1 (carnitine) was calculated, and the Pearson’s correlation 
coefficient was determined for these molecules across three sections 
from each of three SPF mice. The results indicate significant overlap 
between the signals and spatial colocalization between 3M-4-TMAB 
and 4-TMAP and carnitine in the brain (Pearson’s correlation: SPF1, 
0.921547; SPF2, 0.906855; SPF3, 0.609946), alongside a number of 
other molecules that had a Pearson’s correlation coefficient over 0.8 
(Fig. 4). The Pearson’s correlation coefficient was also determined 
for m/z 160.1 and m/z 162.1 in GF mouse brains, and the presence 
of these was found not to correlate (Pearson’s correlation: GF1, 
−0.12976; GF2, −0.00027; GF3, 0.177441; fig. S6). This further sug-
gests that the signal at m/z 160.1 detected in the GF mouse brain 
could result from molecules of similar mass (as described in fig. S1B) 
that could not be resolved in the present study. To ensure that mo-
lecular colocalization in SPF mice was underlying the correlation, as 
opposed to tissue-based changes in ion suppression, total ion count 
normalization was also applied before analysis. This indicated that 
carnitine at m/z 162 is in the top 3 highly correlated molecules with 
3M-4-TMAB/4-TMAP (table S1). Therefore, as well as being struc-
turally similar to carnitine and its precursor, 3M-4-TMAB and 
4-TMAP were also found in the same locations within the brain.
Following the structural characterization of the 3M-4-TMAB and 
4-TMAP metabolites, standards of each were synthesized and used 
to quantify the endogenous concentration in the SPF brain through 
MSI. 3M-4-TMAB and 4-TMAP were determined to be present at 
equimolar levels in bacterial samples by NMR (Fig. 3); therefore, 
standards of 3M-4-TMAB and 4-TMAP were equally mixed, and a 
concentration curve was generated by spotting defined concentrations 
of this standard on GF brain before MSI analysis. This was used to 
determine the concentration of the endogenous metabolites in the 
SPF brain. The average concentration across the whole brain of the 
metabolites was determined to be 0.37 to 0.4 M. The average 
concentration across the corpus callosum and hippocampus was 
higher, around 13 to 17.1 M, indicating a notable accumulation of 
3M-4-TMAB/4-TMAP in these areas (Fig. 5 and fig. S7).
Considering the level of structural similarity and spatial colocaliza-
tion that was observed between bacterial 3M-4-TMAB and 4-TMAP 
and host carnitine, we hypothesized that these bacterial molecules may 
inhibit carnitine function in host cells. Using synthetic 3M-4-TMAB 
and 4-TMAP, we tested their ability to inhibit mitochondrial function 
in the presence of carnitine in a primary murine cell culture model 
of central nervous system (CNS) white matter (13) using the XF 
palmitate–bovine serum albumin (BSA) FAO substrate on a Seahorse 
analyzer (Seahorse Bioscience). This assay measures FAO using the 
oxygen consumption rate (OCR) as a readout, therefore allowing us to 
evaluate whether a molecule is capable of inhibiting FAO. Murine 
spinal cord–derived cells were grown for 8 days in vitro before being 
assayed in the presence of 0.5 mM carnitine and 3M-4-TMAB and 
4-TMAP, either individually or in combination, at 2 mM for 24 hours. 
FAO was significantly inhibited by 3M-4-TMAB alone (reduced by 
12% across four biological replicates), by 4-TMAP (14% reduction), or 
by an equimolar mixture of 3M-4-TMAB/4-TMAP (17% reduction) 
(Fig. 6). The inhibition seen is comparable to that for etomoxir 
(25% reduction), an irreversible inhibitor of FAO. In addition, testing 
3M-4-TMAB and 4-TMAP in combination at 20 M, in the absence 
of carnitine supplementation into culture and assay media, indicated 
that 3M-4-TMAB and 4-TMAP, at concentrations similar to those 
found in the murine brain, could significantly reduce FAO in white 
matter cells (fig. S8).
Fig. 2. DESI-MSI was used to screen intestinal bacteria for the production of 
metabolites of interest. Bacterial cultures were grown on solid FAB agar, and colonies 
were resuspended in PBS to OD600 (optical density at 600 nm) of approximately 0.3. 
Two microliters was allowed to air-dry on a slide before MSI. Bacterial strains tested: 
(A) C. symbiosum LM19R, (B) C. symbiosum LM19B, (C) C. clostridioforme LM41A, 
(D) C. symbiosum LM42D, (E) Bifidobacterium animalis LM33, (F) Lactobacillus animalis 
LM31, (G) Propionibacterium spp. YM23, (H) Clostridium difficile LM27, (I) Enterococcus 
faecalis YM13, (J) Bacteroides fragilis NCTC 9343 (type strain), (K) C. clostridioforme 
NCTC 11224 (type strain), (L) C. clostridioforme NCTC 7155 (type strain), (M) blank 
control, (N) blank control, (O) C. symbiosum LM19R, and (P) Escherichia coli F18.
 o
n
 April 7, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Hulme et al., Sci. Adv. 2020; 6 : eaax6328     11 March 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
4 of 10
The application of a multidisciplinary approach and novel imaging 
methodologies here has enabled the elucidation of molecular mim-
icry as another means of communication across the MGB axis. 
Microbe-mitochondria cross-talk may be an important means of gut 
microbiome–host communication, and its biological importance in 
diseases where mitochondrial dysfunction and the gut microbiome 
are significant factors is likely underappreciated.
DISCUSSION
Alterations in the gut microbiome have been linked to a number of 
neurological conditions, meaning that understanding the means of 
microbial communication across the MGB axis is of increasing im-
portance. This study identifies two novel gut microbiome–derived 
carnitine mimics that significantly colocalize with carnitine in the 
white matter of the murine brain while also inhibiting carnitine 
function in in vitro models of murine CNS white matter. FAO supplies 
up to 20% of brain oxidative energy needs and is critical for many 
neurological functions, with neural stem cells reliant in vitro and 
in vivo on FAO for their survival and proliferation (14, 15). Given 
recent findings underlining the fundamental importance of FAO to 
brain health, the identification of gut microbiome–derived compounds 
in the brain that mediate inhibition of brain cell function is of 
immense importance (15, 16).
Inhibition of mitochondrial function by antimicrobials has been 
reported previously, and there is a growing body of evidence to support 
the existence of microbiome-mitochondria communication within the 
host (17). While carnitine is not needed for fatty acid trafficking in 
microbes, it acts as both a nutrient source and a protectant against 
environmental stress (18). Carnitine metabolism by enteric microbes 
generates trimethylamine N-oxide (TMAO), high serum levels of which 
are indicative of cardiovascular disease risk (19). Intestinal bacteria can 
thrive in the presence of carnitine, but Lachnospiraceae, of which the 
3M-4-TMAB– and 4-TMAP–producing Clostridia XIV are members, 
Fig. 3. 1H-1H COSY of crude extracts showing the occurrence of three related trimethylammonium derivatives. Cross peaks have been colored-coded accordingly, 
while lines shown on the spectrum represent the correlation between neighboring coupling protons in the respective derivative: 3M-4-TMAB (green) and 4-TMAP (red) 
as well as the demethylated congener, GBB (black).
Fig. 4. Conversion of MALDI-MSI into binary images showing the high-intensity 
(black) and low-intensity (gray) regions of the ion images of m/z 160.1 (3M-4-
TMAB/4-TMAP) and m/z 162.1 (carnitine). The overlap of these regions was then cal-
culated as the percentage of pixels in the high-intensity region of the m/z 160.1 image 
that were also high intensity in the m/z 162.1 image. In addition, Pearson’s correlation 
coefficient between the two images was calculated for each tissue across three biolog-
ical replicates (SPF1, SPF2, and SPF3), with a coefficient of 1 indicating perfect colocaliza-
tion and −1 indicating no colocalization whatsoever (SPF1 overlap 92.85714, Pearson’s 
correlation coefficient 0.921547; SPF2 93.20652, 0.906855; SPF3 63.20542, 0.609946).
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decrease in its presence likely as a result of being outcompeted by 
carnitine-metabolizing bacteria (19). Under such competitive con-
ditions, we speculate that carnitine mimics such as 3M-4-TMAB and 
4-TMAP may be produced by these Lachnospiraceae in an attempt to 
inhibit carnitine function or metabolism in competing bacteria.
C. clostridioforme and C. symbiosum, the identified producers of 3M- 
4-TMAB and 4-TMAP, remain poorly understood. C. clostridioforme 
is now recognized as distinct from C. bolteae and C. hathewayi, two 
species that were previously classified as C. clostridioforme (10). 
C. bolteae rapidly proliferates after disruption of the human gut 
microbiota, likely because of its ability to form endospores and 
resistance to multiple antibiotics, traits also found in C. clostridioforme 
and C. symbiosum (20, 21). C. bolteae exhibits a marked ability to 
proliferate and persist in the human intestine post-antibiotic use, 
maintaining its presence for 180 days after treatment (20). The presence 
of C. symbiosum and C. clostridioforme in the gut microbiome is 
associated with low microbial diversity, while C. symbiosum pres-
ence could further distinguish obese from lean participants (22). The 
link between C. symbiosum and metabolism is further underlined 
by its ability to promote robust weight gain in growth-stunted mice, 
one of only two bacteria that exhibited the capability (23). Whether 
3M-4-TMAB and 4-TMAP could play any role in these metabolic 
effects warrants further investigation, but we hypothesize that under 
conditions that are favorable to increased colonization by these mi-
crobes, the production of 3M-4-TMAB and 4-TMAP in the intes-
tine is likely to increase significantly with potential systemic effects.
While 3M-4-TMAB is a molecule not previously described in 
the literature, 4-TMAP has been chemically synthesized as an analog 
of mildronate, a potent inhibitor of both human GBB hydroxylase 
(BBOX1) and carnitine acetyltransferase (CrAT) enzymes (24). These 
enzymes are involved in carnitine synthesis and the transport of fatty 
acids into mitochondria, respectively. 4-TMAP is bound in the human 
BBOX1 active site in a near- identical conformation to mildronate 
and has a lower dissociation constant (4.1 M) but was found to have 
an inhibitory concentration (IC50) nearly three orders of magnitude 
higher than mildronate (24–26). This means that the inhibitory effects 
seen here are likely mediated by targeting of carnitine-related enzymes 
other than BBOX1 and CrAT. 3M-4-TMAB bears marked structural 
similarity to a number of known inhibitors of carnitine function, includ-
ing aminocarnitine derived from the fungal compound emericidin 
(27). Aminocarnitine inhibits carnitine palmitoyltransferase 1 (CPT1) 
and CPT2, and CrAT as the hydroxyl group essential to carnitine 
metabolism has been substituted with an alternate nonfunctional 
side chain. Removal of this hydroxyl group, which is also absent 
in 3M-4-TMAB and replaced with a methyl group, prevents the 
esterification reaction needed to link a long-chain fatty acid to 
carnitine, thereby inhibiting fatty acid shuttling into the mitochondria 
for oxidation. Future research focusing on a role for metabolites 
Fig. 5. Quantitation of 3M-4-TMAB and 4-TMAP in the mouse brain was performed using DESI-MSI of m/z 160.133. (A) An equimolar mix of 3M-4-TMAB and 4-TMAP 
standards was prepared and spotted on a GF brain section at various concentrations. (B) The m/z 160.133 ion intensity of each spot from the MSI results was used to 
generate a concentration curve against the amount of standard in each spot. (C) The concentration curve was used to calculate the average endogenous concentration 
of 3M-4-TMAB and 4-TMAP across the whole brain and across the high abundance area, the corpus callosum, and the hippocampus region. The high abundant region is 
outlined in (A). The results show two technical replicates for GF and SPF brain sections.
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from the gut microbiome in the inhibition of mitochondrial func-
tion across a wide range of mammalian tissues and cell types may 
be highly informative. Such work has the potential to yield signifi-
cant insight into how the gut microbiome influences the host system-
ically, not just across the MGB axis.
While difficult to determine without further detailed confirma-
tory tests, the presence of 3M-4-TMAB and 4-TMAP in other dis-
eases is suggested through publicly available data and the literature. 
A molecule of the exact m/z of 3M-4-TMAB and 4-TMAP (160.133) 
has been described in the literature as a biomarker in type 2 diabetes 
(T2D), significantly increased in cord plasma during preeclampsia, 
and predictive of diabetic nephropathy in T1D patients (28–30). 
These diseases all have associated mitochondrial dysfunction or 
incomplete FAO. The likelihood of the biomarker at m/z 160.133, 
which is significantly increased in T2D patients, being 3M-4-TMAB 
and 4-TMAP, is further supported by separate studies in Europe 
and China, in which the 3M-4-TMAB/4-TMAP–producing strains 
were the most significantly enriched species in the T2D gut 
microbiome (31, 32). C. symbiosum has shown promise as a bio-
marker for early and noninvasive detection of colorectal cancer, 
while a molecule of m/z 160.1 was detected as one of the three most 
significantly correlated molecules to hypoxic regions in breast cancer 
tumors (33, 34). The product ion spectra produced from the MS/MS 
analysis of the metabolite in the breast cancer tumor model match 
the spectra from 3M-4-TMAB and 4-TMAP, indicating that they are 
likely the same and that 3M-4-TMAB/4-TMAP can penetrate tumors.
The interplay between the microbiome and host mitochondria is 
likely far more extensive and complex than presently known, with 
many diseases of mitochondrial dysfunction correlated to well- 
described changes in microbial populations in the gut (17, 31, 35). 
Mitochondrial dysfunction is also common across a range of neuro-
logical conditions, with neuronal cells highly dependent on dynamic 
mitochondria to meet their high energy requirements (16, 36, 37). A 
number of ASDs have been linked to underlying mitochondrial 
dysfunction, with descriptions in the literature describing increased 
acylcarnitine levels, decreased FAO-mediated stem cell generation, 
and carnitine-mediated improvement in symptoms (16, 38). While 
the significance of alterations in the gut microbiota in ASD remains 
controversial, both of the 3M-4-TMAB/4-TMAP–producing strains 
identified here have been described in elevated numbers in the gut 
while being at low levels or completely absent in controls (39). 
These microbiome changes are mirrored in murine ASD models 
such as the maternal immune activation (MIA) model, with increases 
in Lachnospiraceae again noted (4). After treatment decreased 
Lachnospiraceae numbers in the intestine of the MIA model, 
improvements in communicative, stereotypic, anxiety-like, and sen-
sorimotor behaviors were all noted, along with a correction in 
defective fatty acid metabolism. These mitochondrial deficiencies, 
alongside those described in other neurological conditions such as 
Parkinson’s and Alzheimer’s disease, mean that any potential role 
for microbiome input into mitochondrial inhibition is worthy of 
further investigation.
This is the first mechanistic description of a microbial molecule 
inhibiting the function of the mitochondria in cells of the CNS. The 
two novel molecules produced by the gut microbiome described 
here are the first found in the murine brain that localize with and 
antagonize the function of carnitine. Given their potency at the 
physiological concentrations found in the murine brain, our findings 
indicate that neurological conditions, where mitochondrial dys-
function has been described and where disturbances in the gut 
microbiome are noted, should be looked at with increased emphasis 
on potential for microbiome input.
MATERIALS AND METHODS
Animal work
Seven- to 8-week-old male C57BL/6J GF and SPF mice were sourced 
from the University of Manchester, Gnotobiotic Facility. Both GF 
and SPF mice were fed the same pelleted diet, which was sterilized 
by irradiation with 50 kGy. The Manchester Gnotobiotic Facility was 
established with the support of the Wellcome Trust (097820/Z/11/B) 
using founder mice obtained from the Clean Mouse Facility, 
University of Bern. For determination of bacterial metabolites in organs 
other than the brain and to determine the effects of antibiotic treat-
ment on the production of 3M-4-TMAB/4-TMAP in the intestine, 
C57BL/6J mice that were age- and sex-matched to GF mice were 
sourced from the University of Glasgow. For antibiotic treatment, 
mice were administered gentamicin (1 mg/ml), neomycin (1 mg/ml), 
and vancomycin (0.5 mg/ml) in sterile distilled drinking water for 
7 days. Approval for these procedures was given before their initia-
tion by internal University of Manchester and University of Glasgow 
ethics committees and the U.K. Home Office under licenses 70/7815, 
P64BCA712, and P78DD6240.
Tissue processing
Mice were culled by cervical dislocation, and brains and colons were 
immediately dissected. The colons were cut along the length, fecal 
matter was removed, and the colon was rolled and embedded in 2.5% 
carboxymethyl cellulose (CMC) (Sigma-Aldrich). Brains were placed 
unembedded in a mold before freezing using crushed dry ice and 
Fig. 6. OCR was used as an indicator of FAO in the presence of 3M-4-TMAB and 
4-TMAP. Oxidation of palmitate is significantly decreased in primary murine 
myelinating CNS white matter cultures in the presence of carnitine and either 
3M-4-TMAB, 4-TMAP, or a combination of 3M-4-TMAB and 4-TMAP at the indicated 
concentrations. Etomoxir, an irreversible inhibitor of FAO, was used as a control. 
The OCR values shown are relative to the BSA and palmitate condition. Each 
symbol represents the relative mean value for one experiment (n = 4 independent 
experiments). The neural precursors used to generate the model of CNS white 
matter were obtained by pooling dissociated spinal cord cells from all embryos 
from a single pregnant female mouse. A one-sample t test was used to test the 
statistical significance against the relative value 1. P values ≤0.05 were considered 
significant. *P < 0.05 and ****P < 0.0001. Bars represent mean ± SD.
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ethanol. The testis, heart, lung, liver, kidney, spleen, and mesenteric 
lymph nodes were collected from one C57BL/6J mouse, embedded 
in 2.5% CMC and snap-frozen in crushed dry ice and ethanol. Blood 
was collected by cardiac puncture and spotted onto a glass slide and 
allowed to air dry. Both brains and colons were cut using a cryostat 
microtome (Leica) at 10 m thickness at −18°C, and the sections were 
thaw-mounted onto indium tin oxide–coated slides for MALDI- 
MSI and normal glass slides for DESI-MSI. Consecutive brain and 
gut sections next to those taken for MSI were used for hematoxylin 
and eosin staining. All slides were stored at −80°C until analysis.
Matrix application and MALDI-MSI analysis
MALDI was used for the initial analysis to obtain a high lateral res-
olution image to show an accurate distribution of the metabolite in 
the brain. Extensive further analysis was performed using high mass 
resolution DESI analysis for MS/MS experiments, showing that 
the spectra from the metabolites in the SPF brain and the spectra 
produced by the bacteria are highly similar. The increase in mass 
resolution is demonstrated in fig. S9. MSI of brains and guts from 
GF and SPF mice was carried out by MALDI–time-of-flight (TOF). 
The results were confirmed by MSI with a DESI-orbitrap to gain a 
more accurate m/z value. Before matrix application, the slide was 
taken from −80°C and brought to room temperature under a stream 
of air. -Cyano-4-hydroxycinnamic acid (CHCA) matrix was applied 
at a concentration of 5 mg/ml in 50% acetonitrile, 50% water with 
0.1% trifluoracetic acid using an automated matrix applicator (HTX 
Technologies) for eight passes at 75°C, 414 millibar gas pressure, 
80 l/min flow, and 1100 mm/min. The MALDI- MSI experiments 
were carried out on a rapifleX MALDI-TOF instrument (Bruker 
Daltonics) with a 10-kHZ smartbeam laser. Imaging was performed 
at a spatial resolution of 50 m with 600 laser shots per position. 
Results were analyzed using flexImaging 5.0 software, and the data 
were normalized by total ion count.
DESI-MSI analysis
DESI-MSI was performed on an orbitrap mass spectrometer 
(Q Exactive, Thermo Fisher Scientific) equipped with an automated 
Prosolia 2D DESI source (Prosolia OmniSpray 2D). The DESI source 
was modified with the following parameters. The spray tip was 
positioned at 1.5 mm above the sample surface and at an angle of 
75°. The distance between the sprayer to mass spectrometer inlet 
was 7 mm with a collection angle of 10°. The spray solvent was 
methanol/water (95:5, v/v), delivered at 1.5 l/min using a Dionex 
Ultimate 3000 pump (Thermo Fisher Scientific) at a spray voltage 
of 4.5 kV. Nitrogen was used as the nebulization gas at a pressure of 
7 bars. The Q Exactive mass spectrometer was operated using an 
S-Lens setting of 50 V and using m/z range of 65 to 400 in positive 
ionization mode, with a spatial resolution of 100 m for tissue sections 
and 150 m for the blood spot. For acquisition of MS/MS spectra, 
an injection time of 300 ms, automatic gain control target of 
5,000,000, and mass resolution of 70,000 were used. MS/MS analysis 
was performed using various high collision dissociation settings 
(shown in Results) and a mass isolation window of ±0.3 Da. Data 
were converted into imzML format using imzML converter version 
1.1.4.5, and data were visualized using MSiReader version 0.09 (40).
MSI analysis of bacterial spots
To isolate producing bacteria from the murine microbiome, feces 
was isolated from C57BL/6J mice and plated onto FAB agar plates. 
Single isolated colonies of murine gut microbiome bacteria or type 
strains were grown overnight in FAB or on FAB agar. Taxonomic 
assignment for the strains was obtained using the complete 16S 
rDNA sequence from each strain and the “Identify” function in 
EzBioCloud (41). The 3M-4-TMAB/4-TMAP–producing strain, 
designated LM19, was identified as C. symbiosum, being 99.79% 
similar to the C. symbiosum type strain ATCC14940. The second 
producing strain, designated LM41, was identified as being 99.5% 
similar to the C. clostridioforme type strain ATCC25537. Type strains 
used for MSI were from the National Collection of Type Cultures 
(United Kingdom). For MSI analysis, single colonies from FAB agar 
plates were inoculated into 100 l of PBS to give an optical density 
at 600 nm of 0.3. Two microliters of each bacterial culture was spotted 
onto a glass slide and allowed to dry. Slides were stored in a desicca-
tor until DESI-MSI, which was performed using the same DESI-MSI 
parameters as above with a spatial resolution of 200 m.
Nuclear magnetic resonance
Samples (15 mg) were dissolved in 700 l of deuterated water (Sigma- 
Aldrich) and added to a 7-mm NMR tube. Presaturation proton 
NMR experiments were performed by irradiating the water peak at 
4.88 parts per million (ppm), using 128 scans, 15-Hz spin with a 
relaxation delay of 3 s. NMR was carried out using a 400-MHz 
JEOL LA400 FT-NMR spectrometer system equipped with a 40TH5AT/
FG probe (JEOL, Tokyo, Japan). The acquisition of the one- 
dimensional proton spectra (1H NMR) was performed by the pre-
saturation pulse sequence using 128 scans per analysis. Subsequently, 
two-dimensional COSY NMR spectra were also acquired with 64 scans. 
Data points were collected into a plot using spectral widths of 3.93 kHz 
for F1 and F2. The presaturation method was used to suppress the 
solvent signal during acquisition.
Analysis of correlation of m/z 160.133 with carnitine 
in the brain
Data were first converted to imzML using flexImaging (Bruker Daltonics 
version 4.1), and processing was performed using SpectralAnalysis. 
Peaks were picked from a mean spectrum generated without any 
preprocessing using gradient peak detection, and a data cube was 
generated by integrating the area under each peak. All data were 
then exported into MATLAB (version 2017a and statistics and image 
processing toolbox, The MathWorks Inc., Natick, MA) for further 
analysis.
Tissue data were first segmented from background using k-means 
clustering (k = 2, cosine distance). Following this, the images from 
m/z 160.01 and 162.01 (carnitine) were extracted and segmented into 
binary masks of high and low intensity using a k-means clustering 
(k = 2, Euclidean distance). The overlap of these regions was then 
calculated as the percentage of pixels in the high-intensity region of 
the m/z 160.1 image that were also high intensity in the m/z 162.1 image. 
In addition, Pearson’s correlation coefficient between the two images 
was calculated for each tissue.
Synthesis of 3M-4-TMAB and 4-TMAP
All amino acid starting materials were from UkrOrgSyntez Ltd. The 
general procedure of Lukevics was used to prepare the materials (42). 
The method of Tars was used for purification (24).
4-TMAP [rac-4-(trimethylammonio)pentanoate] methyl-N,N′- 
diisopropylcarbamimidate (0.500 ml, 2.75 mmol) was added 
dropwise to a stirred solution of 4-(dimethylamino)pentanoic acid 
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hydrochloride (250 mg, 1.38 mmol) in MeOH (4 ml) at 21°C over 
a period of 1 min under nitrogen. The resulting solution was stirred 
at 21°C for 40 hours. The reaction mixture was concentrated to 
dryness under reduced pressure, and the residue was slurried in 
water (6 ml) for 1 hour. The precipitated urea was removed by filtra-
tion, and the mixture was evaporated to dryness to give a gum. This 
material was dissolved in water (5 ml) and loaded onto a column 
packed with 5 ml of Amberlite IRN78 hydroxide form resin, and 
the column was stoppered for 30 min before being eluted with 
water. Product-containing fractions were combined and evaporated 
under reduced pressure, and the resulting residue was evaporated 
from acetonitrile to give rac-4-(trimethylammonio)pentanoate 
(204 mg, 1.281 mmol, 93%) as a white solid. 1H NMR (500 MHz, 
d6-DMSO) 1.23 (d, J = 6.54 Hz, 3H), 1.29 to 1.39 (m, 1H), 1.76 (ddd, 
J = 6.0, 9.5, 15.5 Hz, 1H), 1.93 (ddd, J = 5.5, 6.45, 15.0 Hz, 1H), 2.1 
to 2.18 (m, 1H), 2.98 (s, 9H), and 3.43 (dqd, J = 2.5, 6.5, 10.5 Hz, 1H); 
13C NMR (126 MHz, D2O, 27°C) 180.9, 71.0, 50.6, 34.2, 26.4, and 
12.7; liquid chromatography (LC)–MS: m/z 160; assay: 79% (w/w) 
(quantitative NMR).
3M-4-TMAB [rac-3-methyl-4-(trimethylammonio)butanoate] 
methyl-N,N′-diisopropylcarbamimidate (0.500 ml, 2.75 mmol) was 
added dropwise to a stirred solution of 4-(dimethylamino)-3- 
methylbutanoic acid hydrochloride (250 mg, 1.38 mmol) in MeOH 
(4 ml) at 21°C over a period of 1 min under nitrogen. The resulting 
solution was stirred at 21°C for 40 hours. The reaction mixture was 
concentrated to dryness under reduced pressure, and the residue 
was slurried in water (6 ml) for 1 hour. The precipitated urea was 
removed by filtration, and the mixture was evaporated to dryness to 
give a gum. The material was dissolved into water (5 ml) and loaded 
onto a column packed with 5 ml of Amberlite IRN78 hydroxide 
form resin, and the column was stoppered for 30 min before being 
eluted with water. Product-containing fractions were combined and 
evaporated under reduced pressure, and the resulting residue was 
evaporated from acetonitrile to give a gum. The material was sonicated 
in diethyl ether (ca. 4 ml), and the solvent was removed by pipette 
to leave a waxy solid that was dried under reduced pressure to give 
rac-3-methyl-4-(trimethylammonio)butanoate (88 mg, 0.553 mmol, 
40%) as a waxy gum. 1H NMR (500 MHz, D2O): 1.18 (d, J = 6.5 Hz, 
3H), 2.23 (dd, J = 7.8, 14.5 Hz, 1H), 2.34 (dd, J = 6.5, 14.5 Hz, 1H), 2.41 
to 2.51 (m, 1H), 3.18 (s, 9H), 3.29 (dd, J = 6.0, 13.5 Hz, 1H), and 3.37 
(dd, J = 3.54, 13.5 Hz, 1H); 13C NMR (126 MHz, D2O, 27°C): 180.17, 
72.37, 53.38, 44.39, 26.62, and 20.13; LC-MS: m/z 160; assay: 74% (w/w) 
(quantitative NMR).
3M-4-TMAB and 4-TMAP quantitation
A stock solution of 3M-4-TMAB and 4-TMAP (AstraZeneca compound 
management) was prepared daily as needed at a concentration of 
1 mg/ml in 50:50 (v/v) methanol/water. The stock solutions (1 mg/ml) 
were subsequently mixed to form a working solution (0.1 mg/ml), 
which was then serially diluted to 11 further working solutions with 
concentrations in the range of 0.00002 to 0.04 mg/ml. Working solu-
tions at 0.00002, 0.00004, 0.0001, 0.0002, 0.0004, and 0.001 mg/ml 
were spotted (50 nl using a Biospotter, Biofluidix, Freiburg, Germany) 
onto GF mouse brain tissue and allowed to evaporate. This depo-
sition of standard translated to 0.001, 0.002, 0.005, 0.01, 0.02, and 
0.05 ng of 3M-4-TMAB/4-TMAP on tissue. DESI-MSI analysis was 
performed using the same parameters as above. Data visualization 
and region of interest extraction were performed using SCiLS Lab 
MVS 2018b (Bruker Daltonics, Bremen, Germany) software typically 
using mass selection window of ±0.05 Da. 3M-4-TMAB/4-TMAP was 
detected as the protonated molecular ion (M+H+) at m/z 160.1. Ex-
tracted mean relative abundance was used from each area of interest 
to construct calibration curves in Microsoft Excel using a linear fit 
with unknown endogenous concentrations calculated using the equa-
tion of a straight line.
Cell culture
CNS myelinating cultures were established as described (13) with 
minor modifications. Briefly, embryonic day 13 (E13; day of plug E0) 
mouse spinal cords were isolated and stripped of their meninges 
and then dissociated into a single-cell suspension using trypsin and 
trituration. Cells were plated at 60,000 to 75,000 cells per well of a 
Seahorse XF96 cell culture plate (35-l volume) pretreated with poly-l- 
lysine [in boric acid buffer (0.1 mg/ml; pH 8.4)]. Cells were plated ini-
tially in 12.5% horse serum, which was gradually withdrawn through 
feeding every second or third day with serum-free differentiation 
medium [Dulbecco’s modified Eagle’s medium (DMEM) (glucose, 
4.5 mg/ml), penicillin (100 U/ml), streptomycin (100 g/ml), biotin 
(10 ng/ml), 1% N1, 50 nM hydrocortisone, and insulin (10 g/ml)]. 
Cells were maintained in 5% CO2 at 37°C.
OCR measurements
On day in vitro (DIV) 8 for CNS myelinating cultures, OCR was 
measured using the XF Cell Mito Stress Test and XF Palmitate-BSA 
FAO substrate on a Seahorse XF96 analyzer (Seahorse Bioscience, 
Billerica, MD). Twenty-four hours before the assay, cultures were 
placed in Substrate-Limited Medium [DMEM supplemented with 
0.5 mM glucose, 1 mM glutamine, 0.5 mM carnitine, and 1% fetal 
bovine serum (FBS)]. Just before the assay, media were changed 
to FAO Assay Medium consisting of KHB buffer (111 mM NaCl, 
4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4, and 1.2 mM NaH2PO4) 
supplemented with 2.5 mM glucose, 0.5 mM carnitine, and 5 mM 
Hepes, adjusted to pH 7.4. To stimulate FAO, palmitate-BSA sub-
strate (200 M) was added to all wells except the BSA control. 
4-TMAP and 3M-4-TMAB effects on FAO were measured by sup-
plementation into wells of 2 mM 4-TMAP or 3M-4-TMAB or 1 mM 
4-TMAP and 1 mM 3M-4-TMAB in combination for 24 hours be-
fore the assay and for the duration of the assay. For examination 
of the effect of the concentrations of 3M-4-TMAB and 4-TMAP 
found in the brain on FAO, the experiment was repeated as before 
but in the absence of carnitine (0.5 mM) supplementation into both 
Substrate-Limited Medium and FAO Assay Medium, meaning that 
FBS was the only exogenous source of carnitine during the assay. 
4-TMAP or 3M-4-TMAB (20 M), or a combination of 10 M 
4-TMAP and 10 M 3M-4-TMAB, was supplemented into media 
for 24 hours before assay and during the assay. OCR was measured 
over time in the presence of either high or low concentrations of 
3M-4-TMAB and 4-TMAP, and at least three repeated measures 
per well were recorded. For each well, the measurements were nor-
malized on the total micrograms of proteins determined at the end 
of the assay with a Pierce BCA Protein Assay kit (Thermo Fisher 
Scientific). The number of replicate wells varied between 5 and 20 
per condition. The values of the repeated measurements were aver-
aged, and a mean value was obtained for each individual well. The 
OCR values per well were further averaged, and a mean value for 
each condition was obtained. Last, the mean value for each of 
the conditions was divided by the value obtained for the condition 
with palmitate and BSA supplementation. These calculations were 
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applied to each of the independent experiments performed, for 
which the relative OCR values are reported in the figure.
Microbiome analysis of antibiotic-treated mice
For preparation of DNA samples for microbiome sequencing, fecal 
samples were defrosted to room temperature and the FastDNA Spin 
Kit for Soil DNA Extraction (MP Biomedicals) was used for DNA 
extraction; 16S ribosomal RNA (rRNA) gene sequencing was 
undertaken at Glasgow Polyomics for analysis of the microbiome. 
In brief, primers that were specific to the V3 and V4 regions were 
used to generate 16S amplicons from 12.5 ng of extracted DNA using 
polymerase chain reaction. The resulting amplicons had dual 
barcodes and adapters added using the Nextera XT v2 adapter sets 
(Illumina). The libraries were combined in equimolar ratios and 
sequenced on a MiSeq (Illumina) instrument using a paired end, 2 × 
300–base pair (bp) sequencing run. Samples were sequenced with an 
average of 50,000 reads.
For data analysis, FastQ files were generated from the sequencing 
data and quality-filtered using cutadapt (43). Cutadapt removes adapter 
sequences from high-throughput sequencing reads with a minimum 
quality of 25 and a minimum length of 250 bp. Paired-end reads 
were combined using PANDAseq and collated into a single FASTA 
file using the Qiime package (44). Further processing and analysis 
were completed using the Qiime wrapper and software.
Statistical analysis
For analysis of FAO, at least three independent experiments were 
undertaken, with each biological replicate shown. For each of the 
conditions tested, the value of OCR was expressed as relative to the 
BSA and palmitate condition, and the significance of the differences 
between conditions was assessed with a one-sample t test (relative 
value = 1, GraphPad Prism 8.1.2). P values ≤0.05 were considered 
significant for all statistical tests.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/11/eaax6328/DC1
Fig. S1. Mass spectra from MALDI-MSI and DESI-MSI experiments with the average spectra 
from GF and SPF mouse brains overlaid.
Fig. S2. MALDI-MSI of organs and blood recovered from C57BL/6 wild-type mice indicated that 
m/z 160.1 was located systemically in all organs tested as well as present in whole blood.
Fig. S3. MALDI-MSI of colon sections from mice treated with antibiotics for 7 days 
demonstrates that the metabolite at m/z 160.1 is decreased in the colon of antibiotic-treated 
mice compared to controls.
Fig. S4. MS/MS analysis of the metabolite found in the brain and the metabolite of the same 
m/z (160.133) produced by C. clostridioforme was undertaken.
Fig. S5. Mass spectra from the MS/MS analysis of the synthesized standard 5-AVAB compared 
to the endogenous metabolite in the brain at m/z 160.133.
Fig. S6. Overlap of the ion images of m/z 160.1 and m/z 162.1 (carnitine) from SPF and GF 
mouse brains and abundance of m/z 160.1 from SPF and GF brains and off-tissue negative 
control area.
Fig. S7. Additional information to fig. S5.
Fig. S8. OCR was used as an indicator of FAO in the presence of 3M-4-TMAB and 4-TMAP at the 
indicated concentrations and in the absence of carnitine supplementation.
Fig. S9. Average mass spectra from MALDI-MSI and DESI-MSI results showing peaks at m/z 
160.133 (3M-4-TMAB/4-TMAP) and m/z 162.112 (carnitine) from GF and SPF mouse brains.
Table S1. Summary of the top correlations with Pearson’s coefficient > 0.5 for m/z 160.1 
(3M-4-TMAB/4-TMAP) for the SPF brain tissue sections shown in Fig. 4.
View/request a protocol for this paper from Bio-protocol.
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